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Opioid dependence disorder and 
comorbid chronic pain: comparison 
of groups based on patient-attributed 
direction of the causal relationship 
between the two conditions
Cassie Higgins1,2 , Blair H Smith2 and Keith Matthews1
Abstract
Background: Chronic pain is highly prevalent in treatment-seeking opioid-dependent patients; therefore, 
this comorbid presentation is an important clinical consideration for both addiction and pain specialists. 
The objectives of the present study were to examine whether the direction of causal attribution of opioid 
dependence disorder and chronic pain resulted in two distinct clinical populations, and, if so, to compare 
treatment received during the 5-year follow-up period.
Methods: Participants comprised opioid-dependent patients with chronic pain who reported a perceived 
causal relationship, in either direction, between the development of these two conditions (n = 252). A 
range of health- and addiction-related instruments were used at study inception. Treatment character-
istics were obtained for the follow-up period from national health registers.
Results: Those reporting that pain caused opioid dependence disorder (n = 174; 69%) were characterised 
by poorer pain-related health, more illicit cannabinoid use (p = 0.031), more frequent illicit use of opioid 
analgesics (p = 0.025) and they were in receipt of higher doses of prescribed opioid analgesics. Those 
reporting that opioid dependence disorder caused pain (n = 78; 31%) were characterised by poorer overall 
physical health (p = 0.002), more severe psychiatric symptoms and more overall drug use (p = 0.001).
Conclusion: Two distinct clinical populations were identified, determined by how participants perceive 
the causal relationship between opioid dependence disorder and chronic pain. These two populations 
have differing clinical profiles and treatment requirements: those reporting that pain caused opioid 
dependence disorder were characterised by poorer pain-related health and more illicit use of drugs with 
analgesic properties; and those reporting that opioid dependence disorder caused pain were character-
ised by more overall use of substances, multiple substance use and more intravenous substance use 
and poorer general health. Identifying the causal direction, where such a relationship exists, could help 
addiction and pain services to develop more effective, individualised treatment strategies.
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Introduction
Chronic pain (CP) is reported in up to 68% of opioid-
dependent patients in receipt of opioid agonist therapy 
(OAT);1 therefore, this comorbid presentation is an 
important clinical consideration for both addiction and 
pain specialists. Patients in OAT with comorbid CP are 
associated with greater medical and psychiatric health 
burdens2,3 in addition to relatively severe and enduring 
substance dependence.4,5 Different disease trajectories 
leading to this comorbid presentation may be associated 
with clinical subgroups that have differing OAT and 
analgesic requirements and distinct profiles of medical 
and psychiatric morbidities that may impact on the 
effectiveness of standardised treatment strategies.
In the only published study to address this so far, 
Ilgen et  al.6 examined the relative temporal onset of 
chronic, non-arthritic pain and substance use disor-
ders (SUDs), which included alcohol, in 632 partici-
pants. They found that 56% (n = 351) reported that the 
onset of SUD preceded that of pain, 38% (n = 243) 
reported that the onset of pain preceded that of SUD 
and the remaining 6% (n = 38) reported that the onset 
of both conditions occurred within the same year. 
Ilgen’s work involved a national survey of the general 
population. In contrast, the present study involved a 
treatment-seeking sample of people diagnosed with 
opioid dependence disorder (ODD), and asked about 
their beliefs about the causal relationship in the devel-
opment of CP and ODD rather than inferring this rela-
tionship based on temporal patterns. For comparison, 
an ICD-10 (International Classification of Diseases) 
diagnosis of opioid dependence (OD) generally corre-
sponds to a Diagnostic and Statistical Manual of Mental 
Disorders (5th edition; DSM-V)7 diagnosis of either 
moderate or severe opioid use disorder. This issue is 
discussed in greater detail in the ‘Method’ section.
While the onset of ODD and CP may be unrelated, 
some patients may develop ODD as a result of analgesic 
opioid exposure8,9 or addiction-like behaviour borne out 
of a desire to control unmanaged pain.10,11 Conversely, 
pain may develop in patients with ODD as a result of 
opioid-induced hyperalgesia,12 which is more evident in 
patients with ODD than in patients with CP,13 or due to 
the higher risk of physical injury14,15 and the sequelae of 
substance use.16 In a comprehensive examination of this 
topic, Manhapra et al.11 suggest that patients with CP 
who are prescribed long-term opioid analgesia may 
develop an iatrogenic syndrome, referred to as complex 
persistent opioid dependence (CPOD). CPOD is con-
sidered as a clinical condition distinct from opioid use 
disorder with comorbid CP. In contrast to the clinical 
presentation of patients with opioid use disorder (opioid 
use-related social, occupational and behavioural prob-
lems), CPOD is characterised by poor pain control, 
declining function, psychiatric and medical instability, 
and aberrant behaviours.11 As the authors further high-
light, people with CPOD require different treatment 
approaches to those with a primary diagnosis of opioid 
use disorder and are likely to feel alienated by such a 
diagnosis. The principal aim of the present study was to 
establish whether patients whose ODD led to CP pre-
sented with different clinical profiles and treatment 
requirements from patients whose CP led to ODD. Two 
hypotheses were examined:
1. Among people who had both ODD and CP, 
two clinically distinct groups would be identi-
fied based on the patient-attributed direction of 
the causal relationship between CP and ODD;
2. The characteristics associated with treatment 
for ODD and CP would differ between these 




Participants were drawn from the cohort of patients 
treated in an NHS (National Health Service) Substance 
Misuse Service in a Scottish Health Board area. Patients 
are accepted for treatment within this service if, on 
assessment, they are diagnosed with OD in accordance 
with the World Health Organization’s ICD (ICD-10, 
code F11.2). To avoid confusion, the term, ‘opioid 
dependence disorder’ (ODD), has been used through-
out, since the abbreviation for ‘opioid dependence’ 
(OD) is commonly understood to indicate overdose. An 
integral component in obtaining a diagnosis of ODD is 
that patients must demonstrate increasing tolerance to 
opioids and a physical withdrawal state on cessation of 
opioids. On acceptance into treatment, patients com-
mence OAT, which, at the time of the present study, 
comprised methadone maintenance therapy exclusively. 
OAT opioid prescriptions were administered by the 
NHS Substance Misuse Service; however, opioid anal-
gesic prescriptions, where applicable, were administered 
by other NHS services, largely within the primary care 
setting. For comparison, there are two ICD-10 codes 
that correspond to a DSM-V diagnosis of OUD: (1) 
F11.1 (‘opioid abuse’); and (2) F11.2 (‘opioid depend-
ence’). Generally, the former corresponds to a DSM-V 
diagnosis of mild OUD, and the latter corresponds to 
DSM-V diagnoses of moderate or severe OUD.
Participants recruited to the present study were 
those with CP who were in treatment in the service and 
who reported a perceived causal relationship, in either 
direction, between the development of CP and ODD. 
Patients who reported no causal relationship were 
Higgins et al. 3
excluded from the study since they were considered to 
form a relatively heterogeneous group, characterised 
by the absence, rather than presence, of clinical charac-
teristics in common. Three temporal thresholds have 
been established to identify CP: 3, 6 and 12 months.17 
The present study used the 12-month threshold since, 
in a clinical population familiar with persistent, debili-
tating conditions, this was considered as the best indi-
cation of truly ‘chronic’ pain, an approach that has 
been used in other studies.4,18 Those that reported hav-
ing had pain for less than 12 months were excluded 
from the study since they were considered to form a 
small, relatively heterogeneous group. No participants 
were lost during the course of the study: as discussed 
below, since only anonymised data were used, partici-
pants were not required to consent to participation.
Materials
The 9-item Brief Pain Inventory – Short Form 
(BPI-SF)19 was designed to assess the sensory and 
reactive dimensions of pain. The BPI-SF has demon-
strated adequate validity and reliability in patients with 
CP20 and in patients receiving OAT.21 In the current 
sample, the BPI-SF evidenced excellent internal con-
sistency (Cronbach’s α = .91). Following the adminis-
tration of the BPI-SF, three additional questions were 
asked: (1) ‘For how long have you had your current 
pain problem?’; (2) ‘Do you believe that your pain 
problem was taken seriously by your doctor?’ and (3) 
‘Do you believe that your pain problem caused your 
ODD, that your ODD caused your pain problem, or 
that they are unrelated?’.
The 60-item Maudsley Addiction Profile (MAP)22 
was designed for research purposes in populations with 
drug and/or alcohol problems. This instrument was used 
to determine illicit use of specific substances, frequency 
of use (number of days used in the preceding 30 days and 
amount used on a typical day) and route of administra-
tion (oral, snort/sniff, smoke/case, intravenous (IV) and 
intramuscular). The specific illicit substances listed in 
the MAP are heroin, methadone, benzodiazepines, 
cocaine powder, crack cocaine, amphetamines and can-
nabis. There is also an opportunity to list other illicit sub-
stances used, including the frequency of use and the 
route of administration. Finally, the use and non-use of 
specific substances reported in the MAP was verified by 
performing urinalyses. It is important to note that, while 
the term, ‘illicit’, is used throughout this article, a pro-
portion of patients may have been engaging in nonmedi-
cal use of substances (i.e. use of prescribed medication in 
a non-prescribed manner), which would apply, largely, to 
some patients misusing opioid analgesics and benzodiaz-
epines that had been prescribed to them for therapeutic 
purposes. Scores on the MAP physical and mental health 
subscales range from 0 to 40, and higher scores are asso-
ciated with poorer health. The MAP has demonstrated 
adequate validity in substance users;22 however, its psy-
chometric properties have not been examined in CP 
samples. In the current sample, the MAP demonstrated 
good internal consistency (Cronbach’s α = .88).
The 28-item version of the General Health 
Questionnaire (GHQ-28)23 was designed as a screening 
tool to indicate any psychiatric condition. The Likert-
type scoring method was used and a threshold of ⩾24 
was applied (total scores range from 0 to 84). It has 
been shown to have the ability to accurately detect diag-
noses in accordance with the Composite International 
Diagnostic Interview (CIDI).24 The GHQ-28 has dem-
onstrated adequate validity within opioid-dependent 
populations;25 however, its psychometric properties 
have not been examined in CP samples. In the current 
sample, the GHQ-28 demonstrated good internal con-
sistency (Cronbach’s α = .89).
The 34-item Clinical Outcomes in Routine Evaluation 
– Outcome Measure (CORE-OM)26 assesses the level of 
psychological global distress. Total scores range from 0 to 
136, and a threshold of ⩾34 was used to indicate clinical 
status.27 The CORE-OM has demonstrated adequate 
validity within a healthy volunteer sample;26 however, its 
psychometric properties have not been examined in CP 
or opioid-dependent samples. In the current sample, the 
CORE-OM demonstrated acceptable internal consist-
ency (Cronbach’s α = .80).
The 16-item Social Phobia Diagnostic Questionnaire 
(SPDQ)28 was designed as a diagnostic screening tool 
to identify social phobia in accordance with DSM-IV 
criteria. Using receiver operating characteristic analy-
sis, the authors identified that the optimal balance 
between sensitivity and specificity (both >80%) was 
achieved using a diagnostic threshold of 7.38 (with 
total scores ranging from 0 to 27). The SPDQ has 
demonstrated adequate validity within a sample of 
undergraduate students;28 however, its psychometric 
properties have not been examined in CP or opioid-
dependent samples. In the current sample, the SPDQ 
demonstrated good internal consistency (Cronbach’s 
α = .86).
The 10-item Treatment Perceptions Questionnaire 
(TPQ)29 was designed to measure patient satisfaction 
with OAT treatment. Total scores range from 0 to 40, 
and higher scores represent greater treatment satisfac-
tion. The TPQ has demonstrated adequate validity 
within an OAT sample;29 however, its psychometric 
properties have not been examined in CP samples. In 
the current sample, the TPQ demonstrated acceptable 
internal consistency (Cronbach’s α = .78).
Demographic data were obtained from the NHS 
Community Health Index (CHI) dataset. These data 
comprised gender, age and socioeconomic status using 
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Scottish Index of Multiple Deprivation (SIMD) quin-
tiles (https://www.gov.scot/collections/scottish-index-of-
multiple-deprivation-2020/). In accordance with SIMD 
recommendations, quintiles 1–2 were used to indicate 
relative socioeconomic deprivation and quintiles 3–5 
were used to indicate relative socioeconomic affluence.
Electronic regional extracts were obtained from 
National Services Scotland (NSS): community-dis-
pensed prescribing; general hospital admissions 
(SMR01); and psychiatric hospital admissions (SMR04).
Procedure
The study was incepted on 1 January 2005, and the 
BPI-SF, substance use profiles and psychiatric assess-
ment instruments were completed by all patients. Five-
year follow-up data spanning 2005–2010 were obtained 
from the electronic health registers and linked at using 
the Community Health Index (CHI) number, a unique 
NHS patient identification code. Data were linked 
electronically by the Health Informatics Centre (HIC) 
Services, Dundee, a Scottish government-certified Safe 
Haven, and anonymised prior to release to the research 
team for analysis via a secure web link.
Equianalgesic computations. Morphine-equivalent doses 
were established using an online equianalgesic calculator 
based on the American Pain Society guidelines and criti-
cal review papers30–33 focusing on the issue of equianalge-
sic dosing (http://clincalc.com/opioids/). Buprenorphine 
was not available for conversion in the equianalgesic cal-
culator so the Monthly Index of Medical Specialities 
(MIMS) conversion ratio was used, whereby, a multipli-
cation factor of ×80 was applied to buprenorphine doses 
to identify morphine-equivalent doses.
Equianxiolytic computations. All anxiolytics prescribed 
in the present study were of the benzodiazepine class 
and 98% were diazepam; hence, all doses were con-
verted to diazepam-equivalent doses. A wide range of 
conversion ratios are documented, and the ratios used 
in the present study (based on mode average) are 
detailed in the supplementary material (online Supple-
mental material 1).
Statistical considerations
The Statistical Package for Social Sciences (SPSS v22) 
was used to undertake statistical testing. Chi-square and 
univariate ANOVA analyses were used to examine group 
differences (CP→ODD vs ODD→CP) across a number 
of demographic, substance use, pain-related functioning, 
psychiatric functioning and general functioning meas-
ures. Among demographic characteristics, chi-square 
was used to examine proportional differences in gender 
and socioeconomic status. Univariate ANOVA was used 
to examine differences in age. Among substance use 
characteristics, chi-square was used to examine propor-
tional differences in any illicit heroin, methadone, opioid 
analgesic, benzodiazepine and cannabinoid use in the 
past, as well as across all illicit substance use. Chi-square 
was also used to examine proportion stabilised in OAT 
treatment, proportion experienced excessive hyperhidro-
sis in the past 4 weeks, and prior engagement in IV drug 
use within the past 4 weeks. Univariate ANOVA was 
used to assess group differences in mean number of days 
used in the past 30 days for each substance and mean 
injecting risk score. Among pain characteristics, chi-
square was used to examine proportional differences in 
multiple sites of pain, pain interference, receipt of pre-
scribed opioid analgesics and the perception that pain 
problems were taken seriously by the treating physician. 
Univariate ANOVA was used to assess group differences 
in mean duration of pain, pain intensity and opioid anal-
gesic dose. Among psychiatric assessment characteris-
tics, chi-square was used to examine proportional 
differences in meeting clinical thresholds on specific 
assessment instruments (GHQ-28, CORE-OM and 
SPDQ). Univariate ANOVA was used to assess group 
differences in mean scores on the GHQ-28 subscales 
(social dysfunction, severe depression, somatic symp-
toms and anxiety/insomnia) and the CORE-OM sub-
scales (subjective wellbeing, problems/symptoms, life 
functioning and risk/harm). Among medical and psychi-
atric treatment characteristics, chi-square was used to 
examine proportional differences in receipt of prescribed 
medication and inpatient treatment. Univariate ANOVA 
was used to assess group differences in mean number of 
hospital admissions.
Since multiple comparisons can result in Type I 
errors (i.e. false positive results), the familywise error 
rate was controlled, using a manual Bonferroni’s cor-
rection. The familywise error rate (set at the conven-
tional 0.05) was divided by the number of tests 
associated with one single hypothesis to establish the 
critical value (α) for individual tests. Where the critical 
value was adjusted, this was recorded in the text or 
table footnotes. This relates specifically to assessments 
of patients meeting clinical thresholds on the GHQ-28 
and the CORE-OM, since it could be argued that they 
measure similar constructs. Clinical thresholds associ-
ated with the total scores on these instruments provide 
an indication of psychiatric diagnostic status. They 
were considered to be a family of tests and, therefore, 
the alpha was adjusted accordingly (p ⩽ 0.025).
Ethical approval
Ethical approval was not required for the present study, 
since all data were anonymised and accessed via a 
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national Safe Haven; however, a favourable ethical 
opinion was obtained from the East of Scotland 
Research Ethics Committee (EoSREC).
Results
Of the 615 patients in the NHS Substance Misuse 
Service, 221 (36%) were excluded due to having no pain, 
54 (9%) were excluded due to having pain of less than 
12 months duration and 88 (14%) were excluded due to 
reporting no perceived causal relationship, in either direc-
tion, between the onset of CP and ODD. The remaining 
252 patients (41% of the entire treatment population) 
comprised the present study cohort. Just over two-thirds 
of the study cohort (69%, n = 174) reported the belief 
that CP had caused ODD (the CP→ODD group) while 
the remainder (31%, n = 78) reported the belief that 
ODD had caused CP (the ODD→CP group).
Group differences in sociodemographic 
characteristics and patient-reported 
illicit substance use at study inception
Table 1 shows that the CP→ODD group was signifi-
cantly older than the ODD→CP group. While statisti-
cally significant, it equates to a mean age difference of 
only 2 years. A higher proportion of the ODD→CP 
group reported any illicit substance use in the 30 days 
prior to study inception. When broken down by sub-
stance category, it was found that, across the entire sam-
ple, a higher proportion of the ODD→CP group 
engaged in illicit use of methadone, opioid analgesics 
and cannabinoids in the prior 30 days. Of those who 
reported illicit methadone and illicit heroin use, indi-
viduals in the ODD→CP group endorsed significantly 
more days of use than those in the CP→ODD group. 
Conversely, of those who reported illicit use of opioid 
Table 1. Group differences in sociodemographic characteristics and patient-reported illicit substance use at study 
inception.
CP→ODD ODD→CP
Sociodemographic characteristics n % n % p value (ω)
Gender 0.591 (0.034)
 Male 111 70 47 64
 Female 48 30 27 36
Socioeconomic statusa 0.260 (0.071)
 Socioeconomically deprived 154 91 65 87





σ p value (ηp
2 )
Mean age (years) 35 8 33 6 0.018 (0.024)
Any illicit use of substances in 
the past 30 days
n % n % p value (ω)
Any substance 133 89 67 100 0.001 (0.195)
Heroin 60 40 31 46 0.249 (0.056)
Methadone 45 30 29 43 0.041 (0.129)
Opioid analgesics 18 12 16 24 0.022 (0.154)
Benzodiazepines 49 33 24 36 0.380 (0.031)
Cannabinoids 110 74 58 87 0.031 (0.137)
Mean number of days of use in 





σ p value (ηp
2 )
Heroin 6.63 9 11.06 10 0.033 (0.050)
Methadone 7.96 10 12.97 10 0.039 (0.058)
Opioid analgesics 8.56 11 1.94 2 0.025 (0.147)
Benzodiazepines 9.41 11 8.79 10 0.820 (0.001)
Cannabinoids 22.05 11 22.62 11 0.751 (0.001)
CP: chronic pain; ODD: opioid dependence disorder.
aCalculated using the Scottish Index of Multiple Deprivation (SIMD), whereby quintiles 1–2 represent relative deprivation and quintiles 
3–5 represent relative affluence. The bold values are the p-values that meet statistical significance.
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analgesics, individuals in the CP→ODD group endorsed 
significantly more days of use than those in the 
ODD→CP group. It is important to note that these 
findings pertain to self-reported illicit substance use, 
which does not include medication taken as prescribed.
Group differences in the characteristics 
of ODD and CP at study inception
Table 2 shows that the CP→ODD group was associ-
ated with a longer pain duration and higher mean pain 
intensity at study inception. A higher proportion of the 
ODD→CP group had failed to stabilise in OAT treat-
ment and were using drugs intravenously (IV), and this 
group was associated with a higher health risk as a con-
sequence of IV drug use.
Group differences during the 5-year 
follow-up period in medical and 
psychiatric morbidity, OAT and 
analgesic treatment
At study inception, the ODD→CP group was associated 
with a higher mean score on the Physical Health subscale 
of the MAP (M = 19.39, SD = 7.88) compared with the 
CP→ODD group (M = 16.08, SD = 7.49) (F(1,247) = 
10.034; p = 0.002;ηp
2  = 0.039), indicating significantly 
poorer physical health in this group. Table 3 shows group 
differences in psychiatric morbidity at study inception 
using standardised instruments. Assessments using both 
the GHQ-28 and the CORE-OM, were considered to be 
a family of tests and, therefore, the alpha was adjusted 
accordingly (p ⩽ 0.025).
Table 3 shows that a higher proportion of the 
ODD→CP group was considered to be associated with 
a clinical psychiatric condition (i.e. scoring above the 
cut-off on the GHQ-28 and CORE-OM), and there 
was a higher prevalence of social phobia in this group. 
Furthermore, this group was associated with signifi-
cantly higher subscale scores, indicating greater symp-
tom severity, on three of the four GHQ-28 subscales 
(Social Dysfunction, Somatic Symptoms and Anxiety/
Insomnia) and three of the four CORE-OM subscales 
(Problems/Symptoms, Life Functioning and Risk/
Harm). Table 4 shows the proportion of each group 
that was prescribed medication or admitted to inpa-
tient facilities for the treatment of medical or psychiat-
ric morbidity during the 5-year follow-up period.
Table 4 shows that most participants in each group 
had been in receipt of prescribed medication for the 
treatment of medical morbidity at some point during 
the follow-up period, even after exclusion of all classes 
of analgesic medication. The ODD→CP group was 
associated with a higher number of general hospital 
admissions than the CP→ODD group and spent more 
nights in hospital. There were no group differences 
concerning receipt of prescribed medication for the 
treatment of psychiatric morbidities with the majority 
Table 2. Characteristics of opioid dependence disorder and chronic pain and at study inception.
CP→ODD ODD→CP
Characteristics of opioid dependence disorder
 n % n % p value (ω)
Stabilised in OAT treatmenta 42 25 6 8 0.003 (0.194)
Excessive hyperhidrosis 129 77 57 75 0.702 (0.025)





σ p value (ηp
2 )
Mean score for injecting risk (0–48 scale)b 1.7 4.0 8.8 12.1 0.042 (0.135)
Characteristics of chronic pain
 n % n % p value (ω)
Pain at multiple sites 38 22 18 23 0.827 (0.014)
Pain interference: daily activities 125 76 58 77 0.790 (0.017)





σ p value (ηp
2 )
Mean pain duration (months) 97 93 57 58 0.001 (0.048)
Mean pain intensity (0–100 scale)b 64 21 58 21 0.040 (0.017)
CP: chronic pain; ODD: opioid dependence disorder; OAT: opioid agonist therapy.
aStabilisation was indicated where individuals had been on a consistent daily dose and dosing schedule for at least 3 months.
bHigher scores indicate greater symptom severity. The bold values are the p-values that meet statistical significance.
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Table 3. Group differences in psychiatric morbidity at study inception.
CP→ODD ODD→CP
 N % n % p value (ω)
Clinical threshold on GHQ-28 80 57 49 73 0.018 (0.154)
Clinical threshold on CORE-OM 115 69 63 83 0.017 (0.143)





σ p value (ηp
2 )
GHQ-28 subscales
Social dysfunction (0–21 scale) 7.99 3.12 9.09 3.13 0.012 (0.027)
Severe depression (0–21 scale) 4.73 4.70 5.42 4.93 0.298 (0.005)
Somatic symptoms (0–21 scale) 7.77 3.83 8.86 3.91 0.043 (0.017)
Anxiety/insomnia (0–21 scale) 8.45 4.99 9.84 4.73 0.042 (0.017)
CORE-OM subscales
Subjective wellbeing (0–16 scale)a 7.27 4.41 8.04 5.59 0.211 (0.006)
Problems/symptoms (0–48 scale) 24.0 11.4 30.0 25.2 0.011 (0.026)
Life functioning (0–48 scale)a 17.9 10.8 21.5 13.1 0.025 (0.021)
Risk/harm (0–24 scale) 2.14 3.15 3.09 3.40 0.035 (0.018)
CP: chronic pain; ODD: opioid dependence disorder; GHQ: general health questionnaire; CORE-OM: clinical outcomes in routine 
evaluation-outcome measure; SPDQ: social phobia diagnostic questionnaire.
Note: The assessment of clinical thresholds using the GHQ-28 and CORE-OM were considered to be a family of test, since they assess 
similar domains. In consequence, the critical value for these assessments was adjusted to p ⩽ 0.025. The critical value for all other 
assessments remained at p ⩽ 0.05.
aThese subscales are problem scored; therefore, higher scores are associated with greater symptom severity. The bold values are the 
p-values that meet statistical significance.
Table 4. Group differences during the 5-year follow-up period in prescribed medication and inpatient admissions for the 
treatment of medical and psychiatric morbidity, characteristics of prescribed OAT and analgesic medication, and patient 
perceptions of treatment satisfaction.
CP→ODD ODD→CP
Treatment for medical morbidity n % n σ p value (ω)
Medication for medical morbidity 162 93 74 95 0.595 (0.034)
Medication excluding analgesia 155 89 72 92 0.428 (0.050)





σ p value (ηp
2 )
Mean number of admissions 2.6 2.2 4.6 4.7 0.003 (0.078)
Mean duration of stay (nights) 15 21 45 79 0.002 (0.083)
Treatment for psychiatric morbidity n % n σ p value (ω)
Medication for psychiatric morbidity 155 89 69 89 0.885 (0.009)
Medication for anxiety disorders 115 66 55 71 0.489 (0.044)
Medication for depressive disorders 128 74 56 72 0.770 (0.018)
Medication for psychotic disorders 32 18 9 12 0.885 (0.009)





σ p value (ηp
2 )
Mean number of admissions 2.12 1.49 2.43 1.72 0.627 (0.006)
Mean duration of stay (nights) 23.1 22.1 33.8 49.0 0.002 (0.083)
 (Continued)
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Medication prescribed by Substance Misuse Service n % n σ p value (ω)





σ p value (ηp
2 )
Mean ME OAT methadone dose (mg/day) 104 54 108 54 0.553 (0.001)
Mean DE benzodiazepine dose (mg/day) 34 28 31 26 0.556 (0.003)






σ p value (ηp
2 )
OAT treatment satisfaction score (0–40 scale)a 23 6 21 6 0.019 (0.023)
Medication prescribed for analgesia n % n σ p value (ω)





σ p value (ηp
2 )
Mean ME opioid analgesic dose (mg/day)b 64 61 25 15 0.049 (0.132)
Patient satisfaction with physician attitude 
towards pain problem
n % n σ p value (ω)
Pain problem perceived to have been taken 
seriously by physician
89 63 30 56 0.332 (0.069)
CP: chronic pain; ODD: opioid dependence disorder; ME: morphine-equivalent; DE: diazepam-equivalent; OAT: opioid agonist therapy.
aHigher scores indicate greater treatment satisfaction.
bIncluding methadone where it was prescribed for analgesic purposes. The bold values are the p-values that meet statistical 
significance.
Table 4. (Continued)
of both groups having been in receipt of medication for 
the treatment of anxiety and depressive disorders. A 
higher proportion of the CP→ODD group had been 
admitted to psychiatric hospitals during the follow-up 
period. Conversely, of those that were admitted, the 
ODD→CP group was associated with a higher mean 
number of nights’ stay in hospital during this period. 
Table 4 further shows that the CP→ODD group was 
in receipt of a higher morphine-equivalent opioid anal-
gesic daily dose for the treatment of pain than the 
ODD→CP group. Despite this finding, there was no 
group difference concerning satisfaction with treat-
ment for pain problems. There were no group differ-
ences concerning methadone dose, receipt of 
benzodiazepines or diazepam-equivalent daily benzo-
diazepine dose. The ODD→CP group was, however, 
less satisfied with OAT treatment.
Discussion
Among people with ODD and comorbid CP, we identi-
fied two distinct clinical subgroups, determined by the 
patient-attributed causal relationship between their ODD 
and their CP. Our findings suggest that these two groups 
present as clinically distinct treatment populations. A 
higher proportion of the ODD→CP group reported IV 
drug use and illicit use of methadone, opioid analgesics 
and cannabinoids, and more frequent illicit use of heroin 
and methadone was reported in this group. More fre-
quent illicit use of opioid analgesics was reported in the 
CP→ODD group. While the CP→ODD group was asso-
ciated with poorer pain-related health, the ODD→CP 
group was associated with poorer overall physical health 
and more severe psychiatric symptoms, particularly gen-
eral functioning and anxiety-related disorders. 
Furthermore, we found that the CP→ODD group was in 
receipt of a higher mean morphine-equivalent daily dose 
of opioid analgesics for the treatment of pain than the 
ODD→CP group but there was no difference concern-
ing satisfaction with treatment for pain problems, with 
around 60% of both groups reporting satisfaction with 
treatment. There were no group differences concerning 
methadone dose, receipt of benzodiazepines or mean 
diazepam-equivalent daily dose; however, the ODD→CP 
group was less satisfied with OAT treatment.
Patients in the CP→ODD group reported poorer 
pain-related health and more frequent illicit use of opi-
oid analgesics. Since analgesic effectiveness is associ-
ated with more frequent dosing than is obtained in 
OAT, more frequent illicit use of opioid analgesics in 
this group may indicate efforts to control unmanaged 
pain. Indeed, membership of this group was 
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significantly associated with a longer mean duration of 
pain and a higher mean intensity of pain. This finding 
is consistent with the characteristics of CPOD 
described by Manhapra et al.,11 since the CP→ODD 
group appeared to be focussed primarily on addressing 
their pain problems. Indeed, the CP→ODD group, or 
a substantial proportion of it, may be experiencing 
CPOD. A higher proportion of the ODD→CP group 
reported illicit drug use, use of multiple substances, 
more IV drug use and, generally, more frequent use of 
illicit substances. This is similarly consistent with the 
characteristics of substance misuse discussed by 
Manhapra et  al.:11 this complex profile may indicate 
that many patients in this group continued to struggle 
with illicit substance use. Indeed, a smaller proportion 
of this group was reported to be stabilised in OAT, and 
a higher proportion was associated with risk of harm 
due to drug use. Furthermore, the ODD→CP group 
was in receipt of a lower analgesic dose (but were 
equally satisfied with analgesic treatment) and on a 
comparable methadone dose (but were less satisfied 
than the CP→ODD group with OAT treatment). As 
also suggested by Manhapra et al.,11 it appears that this 
group perceives ODD to be their primary problem 
and, in consequence, a proportion may perceive that 
further OAT treatment, rather than analgesic treat-
ment, would help to attenuate their problems.
Patients in the ODD→CP group were associated 
with more psychiatric morbidity, significantly higher 
psychiatric subscale scores and significantly more nights 
spent in psychiatric inpatient facilities. This finding is 
contrary to that of Ilgen et al.,6 who found no group dif-
ferences concerning lifetime mood and anxiety disor-
ders. Higher rates of psychiatric problems are commonly 
a function of affective distress states associated with opi-
oid withdrawal,34,35 and, in consequence, the findings of 
their study may have been ‘diluted’ by the inclusion of 
patients with other drug and alcohol disorders. Patients 
in the ODD→CP group were also associated with 
poorer physical health, a higher number of admissions 
to general hospitals and a higher mean number of nights 
spent in inpatient facilities. These findings are contrary 
to the work of Manhapra et al.,11 who suggest that peo-
ple with a primary pain problem (i.e. patients with 
CPOD), rather than a primary opioid use problem, are 
likely to experience medical and psychiatric instability. 
They did not, however, characterise opioid-dependent 
people who subsequently develop pain. It may be that 
opioid-dependent patients with comorbid CP present 
with relatively more complex medical and psychiatric 
complications than those without pain – indeed our pre-
vious work has shown this in relation to psychiatric dis-
orders.18 Future research studies might consider 
including a third, comparator group – those with opioid 
use problems and no pain problems.
This is the first study to examine both the patient-
attributed causal direction of ODD and CP and its 
association with health and clinical factors. Ilgen et al.6 
examined the relative temporal onset of pain and 
SUDs. There is an obvious link between exposure to 
opioids and ODD, and the inclusion in Ilgen’s cohort 
of patients who had had any SUD (rather than focus-
ing specifically on opioids) may have resulted in a dilu-
tion of any real effect of opioid use disorder on the 
direction of attribution. Furthermore, in contrast to 
Ilgen’s approach, the present study adopted a patient-
centred approach, in a methadone-maintained sample, 
asking about patients’ beliefs about the causal relation-
ship in the development of CP and ODD rather than 
inferring this relationship based on temporal patterns.
All patients in both of these groups were maintained 
on methadone, and this may not be the best available 
treatment for these groups. Certainly, the CP→ODD 
group appears strikingly similar to the CPOD patients 
described by Manhapra et  al.,11 with poorer pain-
related health and more frequent use of substances 
with analgesic properties. Therefore, the principal 
requirement for this group of patients is the delivery of 
effective analgesia while minimising harm. This might 
involve transitioning to non-opioid analgesics or meth-
adone dose titration;9 however, many patients struggle 
with this approach, developing greater pain severity 
and pain-related functional impairment.11 In this case, 
an alternative approach might involve opioid substitu-
tion with buprenorphine (a partial opioid agonist),9 to 
minimise the harms associated with methadone. 
However, it should be noted that there is evidence to 
suggest that buprenorphine is relatively ineffective at 
reducing pain intensity in patients with comorbid opi-
oid use disorder.36 Given that pain appears to be the 
driver for aberrant behaviours in this group, these 
patients may find non-pharmacological interventions – 
such as physical therapy and training in self-manage-
ment strategies – to be more effective in managing 
their pain while reducing the risk of exacerbating their 
OD. It is difficult to comment in detail on the appro-
priateness of methadone treatment for the ODD→CP 
group, and future studies should consider comparing 
functional outcomes in this group with those of ODD 
patients with no pain. It is clear, however, that patients 
in this group could benefit from inter-agency 
approaches involving general and addiction psychiatric 
services alongside specialist pain services. Our method 
of directly asking patients about the causal relationship 
between CP and ODD, while serving its intended pur-
pose in this study, is not recommended for use in clini-
cal practice. Accurately responding to this question 
demands an understanding of the complexities in the 
relationship between CP and ODD, complete candour 
and faultless recall – unrealistic demands to place upon 
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patients. Instead, there may be a valuable role for gen-
eral practitioners, as the coordinators of medical care, 
in carefully monitoring disease trajectories as symp-
toms develop and ensuring that the most appropriate 
care services are provided.
This is a novel study that examines clinical charac-
teristics in OAT patients with CP as a function of the 
causal relationship between the development of these 
two conditions. The findings suggest that they present 
as two clinically distinct groups; however, further 
research is required in this area. Future studies may 
consider including a third, comparator group com-
prised of those with ODD and no pain. Furthermore, 
the present study reported descriptive statistics; how-
ever, the use of inferential statistics could facilitate the 
identification of causal links regarding CP, OD and 
functional outcomes. In order to direct policy and 
practice, however, experimental studies are required 
that can demonstrate the effectiveness of appropriate 
treatment interventions in each of these clinically dis-
tinct patient groups.
Limitations
The reliance on patients to determine the presence and 
direction of any causal relationship in the development 
of CP and ODD could have resulted in a degree of 
misclassification between groups, since some may have 
attempted to justify drug use as attempts to bring 
about analgesia. The stigma associated with opioid 
misuse – and, more broadly, substance misuse – is cul-
turally pervasive and multifaceted and can, ultimately, 
result in non-engagement or disengagement from 
treatment.37 In addition, patients with severe CP may 
find it more difficult to access care due to mobility 
issues or other functional impairments, and this could 
result in further sample bias. Finally, descriptive statis-
tical analyses are presented in this article; future stud-
ies should consider using inferential statistics to 
facilitate the identification of causal links regarding 
CP, OD and functional outcomes.
Conclusion
Two clinically distinct treatment populations were 
identified based on the causal attribution of these two 
disorders. Those reporting that CP caused ODD were 
characterised by poorer pain-related health and more 
frequent illicit use of opioid analgesics. A higher pro-
portion of those reporting that ODD caused CP was 
associated with illicit use of methadone, opioid analge-
sics and cannabinoids and IV drug use; this group also 
reported more frequent illicit use of heroin and metha-
done and was associated with poorer general health. In 
patients with both ODD and CP, establishing whether 
there is a causal relationship between the two disorders 
and, if so, identifying the direction of that relationship 
could help pain services to develop more effective, 
individualised treatment strategies. For patients report-
ing that ODD caused CP, this might include inter-
agency approaches involving general and addiction 
psychiatric services alongside specialist pain services. 
For patients reporting that CP caused ODD, this may 
include careful monitoring of pain-related health and 
substance use and the delivery of effective analgesia 
while minimising harm using techniques such as dose 
titration, opioid substitution, transitioning to non-opi-
oid analgesics, physical therapy and training in self-
management strategies.
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